New combo aims to fight Drug-Resistant prostate cancer
NCT ID NCT05534646
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether adding carotuximab to the standard drug apalutamide can help men with metastatic castration-resistant prostate cancer that has stopped responding to other treatments. About 100 participants will receive either apalutamide alone or the combination. The study first checks safety in 10 people, then measures how long the cancer stays under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
apalutamide and carotuximab
What this could lead to
If this works, it could offer a new treatment option for men with advanced prostate cancer that has stopped responding to current therapies.
What could go wrong
This is an early phase 2 trial with only 100 participants, so results may not apply to everyone. The combination may cause side effects or fail to improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cedars-Sinai Medical Center
RECRUITINGLos Angeles, California, 90048, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
Contact
Contact
-
City of Hope
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Huntsman Cancer Institute and Hospital
RECRUITINGSalt Lake City, Utah, 84112, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••